Skip to content
HowShorted

Vera Therapeutics, Inc. Class short interest in 2024

In 2024, Vera Therapeutics, Inc. Class's disclosed short interest ran from 13.62% of shares outstanding on 12 Jan 2024 to 11.30% on 31 Dec 2024, a change of -2.32 percentage points. The year's high was 15.31% on 30 Apr 2024 and its low 10.30% on 29 Nov 2024, averaging 12.23% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.54 days on 30 Aug 2024. Full history: Vera Therapeutics, Inc. Class.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Vera Therapeutics, Inc. Class in 2024

2024 in figures

Start of year
13.62% (12 Jan 2024)
End of year
11.30% (31 Dec 2024)
Change
-2.32 pp
High
15.31% (30 Apr 2024)
Low
10.30% (29 Nov 2024)
Average
12.23%
Highest days to cover
17.54 (30 Aug 2024)
SEC filings marked
10

Every report in 2024

Vera Therapeutics, Inc. Class short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 202413.62%7.98
31 Jan 202414.88%2.51results (8-K)
15 Feb 202415.23%5.51
29 Feb 202413.95%6.89
15 Mar 202414.04%6.48
28 Mar 202414.25%8.36results (8-K), 10-K filed
15 Apr 202414.21%4.43
30 Apr 202415.31%7.05
15 May 202411.81%8.09results (8-K), 10-Q filed
31 May 202411.10%8.40
14 Jun 202411.20%8.68
28 Jun 202411.18%6.67
15 Jul 202410.95%12.60
31 Jul 202411.13%11.54
15 Aug 202411.09%12.9110-Q filed, results (8-K)
30 Aug 202411.03%17.54
13 Sep 202411.78%14.25
30 Sep 202411.25%7.63
15 Oct 202411.29%11.21
31 Oct 202411.65%5.61results (8-K)
15 Nov 202410.34%7.0010-Q filed, results (8-K)
29 Nov 202410.30%12.36
13 Dec 202410.74%16.45
31 Dec 202411.30%10.15

See also: Vera Therapeutics, Inc. Class's full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.